0.4145
0.0011 (0.27%)
0.0011 (0.27%)
Upgrade to Real-Time
Regular Market
Volume | 585,037 |
|
|||||
News | - | ||||||
Day High | 0.415 | Low High |
|||||
Day Low | 0.4062 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Akebia Therapeutics Inc | AKBA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.4093 | 0.4062 | 0.415 | 0.4134 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
1,254 | 585,037 | $ 0.4124859 | $ 241,320 | - | 0.30 - 3.35 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
10:43:42 | 100 | $ 0.4145 | USD |
Akebia Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 76.21M | 183.85M | 181.87M | $ 213.58M | $ -117.55M | -1.70 | -0.40 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 1.18M | 2.40% |
Akebia Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKBA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.3979 | 0.42 | 0.3801 | 0.4067508 | 3,871,119 | 0.0166 | 4.17% |
1 Month | 0.4196 | 0.4585 | 0.365 | 0.4031686 | 4,223,631 | -0.0051 | -1.22% |
3 Months | 0.33 | 0.5139 | 0.30 | 0.3831631 | 10,049,398 | 0.0845 | 25.61% |
6 Months | 1.77 | 2.93 | 0.30 | 0.7078555 | 10,357,600 | -1.36 | -76.58% |
1 Year | 2.50 | 3.35 | 0.30 | 1.08 | 6,449,357 | -2.09 | -83.42% |
3 Years | 4.45 | 13.78 | 0.30 | 2.73 | 4,457,374 | -4.04 | -90.69% |
5 Years | 14.69 | 20.25 | 0.30 | 3.27 | 2,960,236 | -14.28 | -97.18% |
Akebia Therapeutics Description
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. |